newie cycle

[rjf190]

ok boys here it goes
im 5'9 185, 9%BF, 22 years old bveen lifting for 4 years about

1-13 Test Enan 500mg EW
1-12 EQ (Boldenone ) 400mg EW
1-14 Arimidex .25mg ED
1-14 Nolva 10mg ED

PCT
15-18 Nolve 20mg
15-18 Arimidex .25mg
Clomid
300mg day 1 / 100mg days 2 through 11 / 50mg days 12 throguh 21
my question is that I wan to make it ONLY A 12 WEEK CYCLE
how would i arrange it differently to do this? also i heard u need EQ for a while so can i still do only a 12 weeke cycle

[Da Bull]

Leave your cycle as is bro....it's a very nice,well thought out cycle.The 1 extra week will help your pct timing and give the EQ enough time to do it's thing.

[magicstick2003]

looks good to go... the only thing i would think is why not do a test only the first go around? at least then you will know how you respond to it... as it is now if sides arise you won;t be sure if its the test or EQ... ( i think you will be fine with how it is though just something to think about)

[rjf190]

yea i have done a lot of reasearch and i have decided to go with EQ as well
my body adapts well to foreign substances (i know AAS are differnt) however, i think to me it is worth the risk
i am a greedy bastard and i want gains fast!

[dirtdawg]

EQ is best when run 12-15 weeks, if you want a shorter cycle, just run test, how many cycles have you run?

[rjf190]

this will be my first, perhaps i should i run test only

[Da Bull]

this will be my first, perhaps i should i run test only

Eq is very mild bro..you'd be better off running this than Deca or dbol for a first.

[dirtdawg]

my second and third cycle i ran test e only an i got good results, my first i used serostim with test e, my next i willrun the test e with EQ, start only with test, then you will see how your body reacts, with EQ, it is mild and you have to stay on for 12-15 weeks, if you want a longer cycle run EQ, if not, do A 10 week test e and run 400-500 mgs a week for 10 weeks, try this, it worked for me
1-10 test e 400 mgs ew
1-10 nolva 10 mgs ed
12-15 nolva 20 mgs ed
12-15 clomid 300/100/50
trib 4 g ed

[fijian]

I am trying product called Anatest. It is testosterone propionate . I am stacking it with stanazol orals. I know what to do with the winnie which I have used in the past but I am doing the test for the first time. I want to do an 8 week cycle. Could someone please help me out with my intake levels from week 1 to week 8.

[kusanagi]

Using Nova every day all the cycle ?

nova reduce some gains... (reduce the igf-1 levels)

[magicstick2003]

I am trying product called Anatest. It is testosterone propionate. I am stacking it with stanazol orals. I know what to do with the winnie which I have used in the past but I am doing the test for the first time. I want to do an 8 week cycle. Could someone please help me out with my intake levels from week 1 to week 8.

start your own thread bro no need to hijack a fellow members..... also do some research... the answers you want are easily found by searching...

[LightWeightBaby]

i see nothing wrong with eq and test for the first cycle i did a 10 weeker with both of them and put on 30 pounds and kept 25.

[Da Bull]

Using Nova every day all the cycle ?

nova reduce some gains... (reduce the igf-1 levels)

Show me 1 study were 10 mgs Ed will reduce IGF levels significantly.

[ImmmtheIceman]

perfect first cycle

[kusanagi]

Show me 1 study were 10 mgs Ed will reduce IGF levels significantly.

Sorry Da bull, its a question...

i based this question in some pubmed abstracts about tamoxifen and IGF-1 levels...


Effect of tamoxifen on lipoprotein(a) and insulin-like growth factor-I (IGF-I) in healthy women.

Decensi A, Robertson C, Ballardini B, Paggi D, Guerrieri-Gonzaga A, Bonanni B, Manetti L, Johansson H, Barreca A, Bettega D, Costa A.

FIRC Chemoprevention Unit, European Institute of Oncology, Milan, Italy. [email protected]

Studies in breast cancer patients have shown that tamoxifen decreases circulating levels of lipoprotein(a) (Lp(a)), an independent risk factor for premature coronary heart disease, and insulin-like growth factor-I (IGF-I), a promising surrogate biomarker for breast cancer. Since a common hormone regulatory pathway has been suggested for both biomarkers, we measured Lp(a) levels for 6 months in 68 healthy women participating in a chemoprevention trial of tamoxifen and correlated its changes with IGF-I. After 1 month, mean Lp(a) levels decreased by 23% with tamoxifen and increased by 6% with placebo (P = 0.033). No further change was observed after 2 and 6 months. Women with abnormal values at baseline (i.e. > 30 mg/dl) showed the highest reduction. The mean levels of IGF-I decreased by 23.5% with tamoxifen and remained stable with placebo, but the changes induced by tamoxifen in Lp(a) and IGF-I levels were uncorrelated. Our results support the observation that tamoxifen may be a suitable preventive option for women with multiple disease risk factors.


And another :


Effects of tamoxifen on insulin-like growth factors, IGF binding proteins and IGFBP-3 proteolysis in breast cancer patients.

Gronbaek H, Tanos V, Meirow D, Peretz T, Raz I, Flyvbjerg A.

Institute of Experimental Clinical Research, Aarhus Kommunehospital, Aarhus University Hospital, Aarhus C, Denmark. [email protected]

BACKGROUND: Recently an association between increased serum insulin-like growth factor I (IGF-I) levels and the development of breast cancer was demonstrated. Tamoxifen used in the postoperative treatment of breast cancer patients may exert significant effects on the IGF-I system. MATERIALS AND METHODS: To examine the effect of Tamoxifen treatment (20 mg/day) on changes in the IGF-I axis in 11 breast cancer patients before and after 4 months of Tamoxifen treatment and compared to 8 healthy subjects. IGF-I, IGF-II, IGFBP-1, IGFBP-2, IGFBP-3 and IGFBP-6 were examined by specific assays. IGFBPs were examined by Western ligand blotting and IGFBP-3 proteolytic activity by specific protease assay. RESULTS: Serum IGF-I was decreased before (63%) and increased during Tamoxifen treatment (60%). Total IGFBP-3 levels measured by IRMA were unchanged, however, intact IGFBP-3 measured by WLB was decreased (58%) before and increased (67%) during Tamoxifen treatment. IGFBP-3 proteolysis was increased before and reduced during treatment. IGFBP-4 and IGFBP-6 were decreased before and increased during Tamoxifen treatment. CONCLUSION: Significant changes in the IGF system were demonstrated before and during Tamoxifen treatment and may in part be involved in the effects of Tamoxifen treatment in breast cancer patients.